IDEXX Laboratories, Inc. (IDXX) AI Stock Analysis

IDEXX Laboratories, Inc. develops, manufactures, and distributes diagnostic products and services primarily for veterinary, livestock, poultry, dairy, and water testing markets. Operating through segments including CAG, Water Quality Products, LPD, and Others, the Westbrook, Maine-based company offers companion animal point-of-care instruments, rapid assay kits, reference laboratory services, practice management systems, and diagnostic imaging. It also supplies livestock, poultry, and dairy health-monitoring tools, water microbiology testing products, and human medical point-of-care analyzers. IDEXX sells its solutions globally through direct sales teams, independent distributors, and reseller networks.

Revenue grew from $3.22B in FY2021 to $3.37B in FY2022, $3.66B in FY2023, $3.90B in FY2024, and $4.30B in FY2025, representing a 5-year revenue CAGR of 9.7% from FY2020. Annual net income expanded from $744.8M in FY2021 to $1.06B in FY2025, while diluted EPS grew from $8.61 to $13.07. Gross margin widened from 58.8% in FY2021 to 61.8% in FY2025, and operating margin increased from 29.0% to 31.6%. In the trailing twelve months, revenue reached $4.55B with an operating margin of 35.0% and EPS of $14.07. For the latest quarter ended June 30, 2026, quarterly revenue grew 9.7% and quarterly earnings increased 17.6% year-over-year.

As of June 30, 2026, IDEXX held $196.9M in cash and short-term investments against total debt of $1.10B, resulting in net debt of $899.1M. Shareholders' equity stood at $1.61B on total assets of $3.44B, reflecting a debt-to-equity ratio of 0.68 and a current ratio of 1.17. During FY2025, the company generated $1.18B in operating cash flow and $1.05B in free cash flow, deploying $124.7M toward capital expenditures and $1.22B toward share buybacks. Five-year share count declined 6.3%.

IDEXX trades at a trailing P/E of 39.8x and a forward P/E of 31.4x, higher than the median of its Nasdaq-100 Healthcare peers of 28.9x and 19.7x, respectively. Its enterprise value stands at $41.98B, with an EV/EBITDA of 26.0x and price-to-sales of 9.7x, compared to peer medians of 20.9x and 6.5x. Over the past year, the stock declined 12.1% compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 11.8%, while the S&P 500 rose 83.0%.

Wall Street coverage consists of 4 Strong Buy, 4 Buy, 5 Hold, 1 Sell, and 0 Strong Sell ratings. The mean price target is $705.50, representing an upside of 25.9% from the last close of $560.36 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate revenue of $4.72B and EPS of $14.84, reflecting 13.5% EPS growth. IDEXX has topped EPS estimates in each of the last 4 quarters, with its next earnings date scheduled for November 2, 2026.

This page is an AI-written research summary of IDEXX Laboratories, Inc. (IDXX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IDXX income statement, IDXX balance sheet, IDXX key metrics, IDXX analyst forecast, IDXX chart. See the IDXX stock overview for the latest quote and news.